Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market

Detalhes bibliográficos
Autor(a) principal: Roxo, Ana Paula da Silva
Data de Publicação: 2022
Outros Autores: Valverde Macedo , Elizabeth, Mourão , Samanta Cardozo, Barros, Thalita Gonçalves, Moura de Araújo, Emeli, Peregrino, Carlos Augusto de Freitas, Salles, Marcela Miranda
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Vigilância Sanitária em Debate
Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008
Resumo: Introduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity.
id FIOCRUZ-9_85fa80ac3b9f927193d56722d76e042d
oai_identifier_str oai:ojs.visaemdebate.incqs.fiocruz.br:article/2008
network_acronym_str FIOCRUZ-9
network_name_str Vigilância Sanitária em Debate
repository_id_str
spelling Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the marketFitovigilância: avaliação das interações e reações adversas de fitoterápicos no mercadoVigilância SanitáriaFitovigilânciaReações AdversasFitoterápicosEixo: Vigilância sanitária e sociedadeHealth SurveillancePhytosurveillanceAdverse ReactionsHerbal MedicinesIntroduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity.Introdução: O uso de plantas medicinais como insumos farmacêuticos ativos vegetais (IFAV), bem como o uso de fitoterápicos e suas associações com outros medicamentos fitoterápicos e os insumos farmacêuticos ativos (IFA) sintéticos, pode resultar em interações que afetem a eficácia e o uso seguro desses. O principal meio de notificações de reação adversa a medicamento (RAM) é a voluntária, o que dificulta a identificação e o monitoramento dessas RAM e retrata a importância da farmacovigilância em nosso país, realçando a necessidade de fortalecimento da cultura de notificação de eventos adversos a medicamentos (EAM). Objetivo: Analisar a ocorrência de RAM relacionada ao uso simultâneo de cinco fitoterápicos a outros sintéticos, descrevendo as possíveis interações IFAV-IFA sintéticos. Método: Foi realizada pesquisa bibliográfica sobre as interações IFAV-IFA sintéticos e suas notificações de RAM pelos principais sistemas de farmacovigilância do mundo. Resultados: Os principais mecanismos de interação entre IFAV-IFA sintéticos envolvem a metabolização pelas enzimas da família CYP450 ou a ação de transportadores de efluxo como a gp-P. Além disso, grande parte dos EAM fitoterápicos podem não estar sendo notificados, gerando possível subnotificação dessas informações no mundo. Conclusões: Sobre RAM contendo IFAV de Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum e Zingiber officinale, foram relatados 7.571 no mundo, classificados por continente, no período de 1971 a agosto de 2021, bem como lista de espécies vegetais da lista do Renisus que apresentam efeitos relatados nas enzimas CYP (1A2, 2C9, 2C19, 2D6 e 3A4), níveis de GSH, UGT e atividade da gp-P.  Instituto Nacional de Controle de Qualidade em Saúde2022-08-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/200810.22239/2317-269x.02008Health Surveillance under Debate: Society, Science & Technology ; Vol. 10 No. 3 (2022): August; 46-57Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 10 Núm. 3 (2022): Agosto; 46-57Vigil Sanit Debate, Rio de Janeiro; v. 10 n. 3 (2022): Agosto; 46-572317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1440https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1482Copyright (c) 2022 Ana Paula da Silva Roxo, Elizabeth Valverde Macedo , Samanta Cardozo Mourão , Thalita Gonçalves Barros, Emeli Moura de Araújo, Carlos Augusto de Freitas Peregrino, Marcela Miranda Salleshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccess Roxo, Ana Paula da SilvaValverde Macedo , ElizabethMourão , Samanta Cardozo Barros, Thalita GonçalvesMoura de Araújo, EmeliPeregrino, Carlos Augusto de Freitas Salles, Marcela Miranda2023-06-27T15:15:33Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/2008Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:15:33Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
Fitovigilância: avaliação das interações e reações adversas de fitoterápicos no mercado
title Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
spellingShingle Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
Roxo, Ana Paula da Silva
Vigilância Sanitária
Fitovigilância
Reações Adversas
Fitoterápicos
Eixo: Vigilância sanitária e sociedade
Health Surveillance
Phytosurveillance
Adverse Reactions
Herbal Medicines
title_short Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
title_full Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
title_fullStr Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
title_full_unstemmed Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
title_sort Phytosurveillance: evaluation of interactions and adverse reactions of herbal medicines on the market
author Roxo, Ana Paula da Silva
author_facet Roxo, Ana Paula da Silva
Valverde Macedo , Elizabeth
Mourão , Samanta Cardozo
Barros, Thalita Gonçalves
Moura de Araújo, Emeli
Peregrino, Carlos Augusto de Freitas
Salles, Marcela Miranda
author_role author
author2 Valverde Macedo , Elizabeth
Mourão , Samanta Cardozo
Barros, Thalita Gonçalves
Moura de Araújo, Emeli
Peregrino, Carlos Augusto de Freitas
Salles, Marcela Miranda
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Roxo, Ana Paula da Silva
Valverde Macedo , Elizabeth
Mourão , Samanta Cardozo
Barros, Thalita Gonçalves
Moura de Araújo, Emeli
Peregrino, Carlos Augusto de Freitas
Salles, Marcela Miranda
dc.subject.por.fl_str_mv Vigilância Sanitária
Fitovigilância
Reações Adversas
Fitoterápicos
Eixo: Vigilância sanitária e sociedade
Health Surveillance
Phytosurveillance
Adverse Reactions
Herbal Medicines
topic Vigilância Sanitária
Fitovigilância
Reações Adversas
Fitoterápicos
Eixo: Vigilância sanitária e sociedade
Health Surveillance
Phytosurveillance
Adverse Reactions
Herbal Medicines
description Introduction: The use of medicinal plants as active plant pharmaceutical ingredients (APPIs) as well as the use of herbal medicines and their associations with other herbal medicines and synthetic active pharmaceutical ingredients (API) can result in interactions that affect the efficacy and safe use of these. The main means of reporting adverse drug reactions (ADR) is voluntary, which makes the identification and monitoring of these ADRs difficult and portrays the importance of pharmacovigilance in our country, highlighting the need to strengthen the culture of reporting adverse drug events (ADE). Objective: To analyze the occurrence of ADR related to the simultaneous use of five herbal medicines with other synthetics, describing possible synthetic APPI-API interactions. Method: A literature search was carried out on synthetic APPI-API interactions and their notifications of ADR by the main pharmacovigilance systems in the world. Results: The main interaction mechanisms between synthetic APPI-API involve the metabolism by enzymes of the CYP450 family or the action of efflux transporters such as P-gp. In addition, a large part of phytotherapeutic AEM may not be being notified, generating possible underreporting of this information in the world. Conclusions: On ADR containing APPI from Ginkgo biloba, Hypericum perforatum, Matricaria recutita, Allium sativum and Zingiber officinale, 7,571 were reported worldwide, classified by continent, in the period 1971 to August 2021, as well as the list of plant species on the list of RENISUS that have reported effects on CYP enzymes (1A2, 2C9, 2C19, 2D6 and 3A4), levels of GSH, UGT and P-gp activity.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
"Peer-reviewed article"
"Artículo revisado por pares"
"Artigo avaliado pelos pares"
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008
10.22239/2317-269x.02008
url https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008
identifier_str_mv 10.22239/2317-269x.02008
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1440
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/2008/1482
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
dc.source.none.fl_str_mv Health Surveillance under Debate: Society, Science & Technology ; Vol. 10 No. 3 (2022): August; 46-57
Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 10 Núm. 3 (2022): Agosto; 46-57
Vigil Sanit Debate, Rio de Janeiro; v. 10 n. 3 (2022): Agosto; 46-57
2317-269X
reponame:Vigilância Sanitária em Debate
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Vigilância Sanitária em Debate
collection Vigilância Sanitária em Debate
repository.name.fl_str_mv Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br
_version_ 1797042046636130304